Indian high court makes landmark verdict on drug patents

In a setback for the makers of branded drugs, the Indian Supreme Court dismissed Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling reshapes the landscape for intellectual property disputes in the country and is likely to affect many other drugmakers. The decision will be an obstacle to bringing new treatments to patients, an executive with Novartis India said.

View Full Article in:

Bloomberg · LiveMint.com/The Wall Street Journal (India) · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA